The Cooper Companies: Expansion of MyDay Capacity As A Vital Factor Driving Growth! 

Cooper Companies reported a record revenue year for fiscal 2024, achieving $3.9 billion primarily driven by strong performances from its two main divisions, CooperVision and CooperSurgical. Each division marked record revenues, with CooperVision contributing $676 million in Q4, a 9% increase, largely due to its silicone hydrogel lenses like MyDay, Biofinity, and clariti. The division continues to hold a strong market position, especially in torics, multifocals, and myopia management despite a soft end to the quarter for the contact lens market. CooperSurgical, reporting $342 million in Q4 revenue (up 12%), benefited notably from growth in its fertility sector, supported by innovative genomics and strategic partnerships aiming to meet rising demands in fertility treatments.